Healthcare Industry News: BioMarin Pharmaceutical
News Release - November 13, 2017
Spruce Biosciences Appoints Camilla V. Simpson to Board of DirectorsSimpson brings 22 years of industry experience to Spruce, a clinical-stage biotech developing a novel treatment for congenital adrenal hyperplasia, a rare endocrine disease
SAN FRANCISCO, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that Camilla V. Simpson, Senior Vice President and Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., has joined the Company's board of directors.
"Having recently emerged from stealth mode to announce our Series A and Phase 2 clinical program for congenital adrenal hyperplasia (CAH), we are rapidly building out our operations and gearing up for an active 2018, from both a clinical and regulatory perspective. As such, I am very pleased to have Camilla join our board and be able to leverage her wealth of knowledge and experience in developing and registering specialty and rare disease products globally from her time at BioMarin Pharmaceutical Inc., Shire and Abbott Laboratories," said Alexis Howerton, Ph.D., Chief Executive Officer of Spruce Biosciences.
Camilla V. Simpson is Senior Vice President and Head of Product Portfolio Development at BioMarin Pharmaceutical Inc. Ms. Simpson is responsible for the Product Development Strategy of BioMarin's rare disease portfolio.
Previously, Ms. Simpson was Group Vice President of Regulatory Affairs at BioMarin, and has 22 years of experience in the industry. She holds a B.Sc. in Science from the National University of Ireland Galway, a B.Sc. Hons in Chemistry from Kingston University, UK and an M.Sc. with distinction in Analytical Chemistry from Birkbeck College, University of London, UK.
"I am delighted to join Spruce's board during an exciting time in the company's evolution," said Simpson. "Over the course of my career, I have had the great pleasure of devising global product development and regulatory strategy for multiple rare disease therapies and am looking forward to leveraging my experience on behalf of Spruce as the company advances its lead program in CAH."
For more information on Spruce Biosciences and its lead clinical program for CAH, which is currently enrolling patients in a Phase 2 trial, please visit sprucebiosciences.com.
About Spruce Biosciences
Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. The Spruce team is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases. Spruce's lead product candidate, SPR001, has a novel and clinically verified mechanism of action (MOA) and is currently in Phase 2 clinical trials for congenital adrenal hyperplasia, a rare disease that is screened in newborns and for which there is not yet an FDA-approved therapy. The Company is headquartered in San Francisco and closed a Series A Financing of $20 million in 2016. For more information on Spruce, please visit sprucebiosciences.com.
Source: Spruce Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.